A new study suggests that a urine-based biomarker test shows promise in forecasting bladder cancer treatment response, which ...
Research at Stanford Medicine suggests that a urine test may. be able to determine which patients will benefit from additional therapy.
Non-muscle-invasive bladder cancer (NMIBC) has a high risk of recurrence and progression among patients without adequate Bacillus Calmette-Guérin.
TARA-002 demonstrates high complete response rates in BCG-naïve NMIBC patients, with 72% achieving CR and 50% maintaining it at 12 months. The treatment involves six weekly bladder instillations, ...
Protara’s lead candidate, TARA-002, has demonstrated durable complete response (CR) rates in a single-arm Phase II trial in Bacillus Calmette-Guérin (BCG)-naïve non-muscle invasive bladder cancer ...
Clinical and genomic correlates of brain metastases in small cell carcinoma of the bladder. This is an ASCO Meeting Abstract from the 2026 ASCO Genitourinary Cancers Symposium. This abstract does not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results